Marizyme, Inc. (MRZM)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.71 Million USD | 248.59% |
| 2022 | 5.36 Million USD | 84.23% |
| 2021 | 2.91 Million USD | 121.16% |
| 2020 | 1.31 Million USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 100.0% |
| 2017 | -2396.00 USD | -102.75% |
| 2016 | 87.21 Thousand USD | -91.92% |
| 2015 | 1.07 Million USD | 4183.86% |
| 2014 | 25.18 Thousand USD | -95.7% |
| 2013 | 585.77 Thousand USD | -84.27% |
| 2012 | 3.72 Million USD | 63.94% |
| 2011 | 2.27 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 4865.00 USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 23.55 Million USD | 25.85% |
| 2024 Q2 | 20.45 Million USD | -13.17% |
| 2023 FY | 18.71 Million USD | 248.59% |
| 2023 Q2 | 14.35 Million USD | 81.44% |
| 2023 Q4 | 18.71 Million USD | -13.33% |
| 2023 Q3 | 21.59 Million USD | 50.48% |
| 2023 Q1 | 7.91 Million USD | 47.32% |
| 2022 Q1 | 1.7 Million USD | -41.64% |
| 2022 Q2 | 2.75 Million USD | 61.75% |
| 2022 Q4 | 5.36 Million USD | 56.14% |
| 2022 FY | 5.36 Million USD | 84.23% |
| 2022 Q3 | 3.43 Million USD | 24.98% |
| 2021 Q4 | 2.91 Million USD | 44.3% |
| 2021 FY | 2.91 Million USD | 121.16% |
| 2021 Q2 | 1.51 Million USD | 18.0% |
| 2021 Q1 | 1.28 Million USD | -2.7% |
| 2021 Q3 | 2.01 Million USD | 33.49% |
| 2020 Q4 | 1.31 Million USD | 0.0% |
| 2020 FY | 1.31 Million USD | 0.0% |
| 2020 Q2 | 1000.00 USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | -100.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q3 | 77.19 Thousand USD | 0.0% |
| 2018 Q1 | - USD | 100.0% |
| 2018 FY | - USD | 100.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q4 | - USD | -100.0% |
| 2017 Q4 | -2396.00 USD | 0.0% |
| 2017 FY | -2396.00 USD | -102.75% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | 87.21 Thousand USD | -91.92% |
| 2015 FY | 1.07 Million USD | 4183.86% |
| 2014 FY | 25.18 Thousand USD | -95.7% |
| 2013 FY | 585.77 Thousand USD | -84.27% |
| 2013 Q4 | 585.77 Thousand USD | -89.66% |
| 2013 Q3 | 5.66 Million USD | 62.63% |
| 2013 Q2 | 3.48 Million USD | 22.91% |
| 2013 Q1 | 2.83 Million USD | -23.9% |
| 2012 FY | 3.72 Million USD | 63.94% |
| 2012 Q4 | 3.72 Million USD | -1.08% |
| 2012 Q3 | 3.76 Million USD | -3.45% |
| 2012 Q2 | 3.89 Million USD | -19.87% |
| 2012 Q1 | 4.86 Million USD | -4.76% |
| 2011 FY | 2.27 Million USD | 0.0% |
| 2011 Q4 | 5.1 Million USD | 5.26% |
| 2011 Q3 | 4.85 Million USD | 211.29% |
| 2011 Q2 | 1.55 Million USD | -31.35% |
| 2011 Q1 | 2.27 Million USD | 0.0% |
| 2010 Q1 | 4.86 Million USD | 0.0% |
| 2010 Q2 | - USD | -100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q3 | 300 Thousand USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | 4865.00 USD | 0.0% |
| 2008 Q2 | 4909.00 USD | 0.9% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | 4865.00 USD | 0.0% |
| 2008 Q3 | - USD | -100.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 54.572% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -354.092% |
| SQZ Biotechnologies Company | 27.47 Million USD | 31.865% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 56.845% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 37.12% |
| Mesoblast Limited | 118.7 Million USD | 84.231% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1873.855% |
| Genus plc | 233.1 Million USD | 91.97% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -538.738% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1293.102% |
| ContraFect Corporation | 2.88 Million USD | -549.687% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2395.666% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -13714.974% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1194.147% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -704.723% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -230.794% |
| MultiCell Technologies, Inc. | 202.58 USD | -9239456.718% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 67.442% |
| EV Biologics, Inc. | 1.49 Million USD | -1152.215% |
| Q BioMed Inc. | 4.1 Million USD | -355.416% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 43.453% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -2870.668% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1423.778% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2444.721% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 89.089% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -44.014% |
| Skye Bioscience, Inc. | 4.61 Million USD | -305.556% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -2007.674% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -13126.228% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -218.808% |
| IMV Inc. | 28.88 Million USD | 35.197% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -72676.912% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -728.801% |
| GB Sciences, Inc. | 1.75 Million USD | -963.913% |
| Alpha Cognition Inc. | 1.22 Million USD | -1433.753% |
| HST Global, Inc. | 98.31 Thousand USD | -18937.515% |
| CSL Limited | 12.18 Billion USD | 99.846% |
| Halberd Corporation | 150 Thousand USD | -12378.329% |
| Enzolytics Inc. | 996.33 Thousand USD | -1778.629% |
| Resverlogix Corp. | 6.49 Million USD | -188.361% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -3819.894% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -7223.192% |
| argenx SE | 20 Million USD | 6.413% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 58.917% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -591.013% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -182956.176% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.519% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -9230.011% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -680.636% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -8063.205% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 72.329% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -518.517% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5103.496% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 7.923% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -12491.315% |
| BioStem Technologies, Inc. | 4.71 Million USD | -297.28% |
| ONE Bio Corp. | 19.71 Million USD | 5.06% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -7381.551% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -7425.528% |
| Agentix Corp. | 50 Thousand USD | -37334.988% |
| LadRx Corporation | 33.6 Thousand USD | -55596.882% |
| Cell Source, Inc. | 9.25 Million USD | -102.26% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2375.191% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2375.191% |
| NovAccess Global Inc. | 2.19 Million USD | -750.842% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -164.64% |
| Itoco Inc. | 228.37 Thousand USD | -8095.875% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8771.901% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -275.627% |
| Kadimastem Ltd | 891.22 Thousand USD | -2000.196% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4557.843% |
| CytoDyn Inc. | 30.07 Million USD | 37.766% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -3764.983% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -5219.782% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -139.355% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -15179.587% |
| Rebus Holdings, Inc. | 310 Thousand USD | -5937.901% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -295.277% |
| International Stem Cell Corporation | 4.17 Million USD | -348.001% |
| Bioxytran, Inc. | 1.92 Million USD | -872.337% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -29889.736% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -758.246% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -125.078% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -118.026% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1103.327% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -6884.14% |
| Neutra Corp. | 54.15 Thousand USD | -34462.18% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -922.814% |
| PureTech Health plc | 25.51 Million USD | 26.633% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1428.925% |
| IXICO plc | 472.02 Thousand USD | -3865.378% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -20.75% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 69.938% |
| CSL Limited | 12.18 Billion USD | 99.846% |
| Cellectis S.A. | 92.77 Million USD | 79.825% |